Baseline Serum Albumin Is a Predictive Biomarker for Patients With Advanced Pancreatic Cancer Treated With Bevacizumab: A Pooled Analysis of 7 Prospective Trials of Gemcitabine-Based Therapy With or Without Bevacizumab

BACKGROUND: Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors’ knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit fro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Pant, Shubham, Martin, Ludmila K., Geyer, Susan, Wei, Lai, Van Loon, Katherine, Sommovilla, Nilli, Zalupski, Mark, Iyer, Renuka, Fogelman, David, Ko, Andrew H., Bekaii-Saab, Tanios
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265390/
https://ncbi.nlm.nih.gov/pubmed/24633933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28648
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars